Navigation Links
Oncolytics Biotech(R) Inc. To Host Conference Call to Discuss Updated U.K. Phase I/II Trial Head and Neck Cancer Data Being Presented at the ASCO Annual Meeting
Date:6/4/2010

June 14th, 2010. To access the telephone replay, dial 1-416-849-0833 or 1-800-642-1687 and enter reservation number 80060184 followed by the number sign.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

The presentation time is subject to change. This press release and the presentations related thereto contain forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the timing, implication and accuracy of materials presented at the ASCO meeting with respect to REOLYSIN, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceutica
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
2. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
3. Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
4. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
5. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
6. Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
7. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
8. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
9. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
10. Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
11. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... (PRWEB) May 21, 2013 ... services company for clinical trials, announced today it ... Solutions, LLC. Clinverse’s ClinPay® FLS eClinical commerce ... payment process. SpendMD ™, Aggregate Spend ... solution for tracking and reporting transfer of value ...
(Date:5/21/2013)... 21, 2013 Many have long discussed ... to acne. Recently physicians from Clinical Psychiatry.com ... on the skin, and suggested using hypnotherapy ... chemicals produced from stress that cause acne. , Doctors ... feelings acne brings about, stress causes changes in the ...
(Date:5/21/2013)... May 21, 2013  Personal Genome Diagnostics Inc. ... proprietary methodologies and expertise in genomic analysis of ... in collaboration with Blueprint Medicines.  PGDx is an ... genomic alterations in tumors, and Blueprint Medicines is ... for a genetically defined patient population. ...
(Date:5/21/2013)... 2013 Inflamax scientists worked closely ... to design the study, which will provide critical ... models used in the study of allergy treatments, ... Challenge (NAC) models. Although both the models are ... date no direct comparison between the allergic responses ...
Breaking Biology Technology:Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2
... MichBio, the association for,Michigan,s life sciences industry, ... and Resources Guide, a complete listing of ... editorial pages with articles,on Michigan,s SmartZones, venture ... Universities Commercialization Initiative,and Core Technology Alliance, as ...
... Sept. 13 /PRNewswire-USNewswire/,-- To address the growing demand ... announced today the launch of its Center,for Biological ... by an,internationally recognized team of certified biosafety and ... range of specialized,laboratory consulting services from design, to ...
... Leaders,in Life Sciences and Clinical Diagnostics to Share ... 13 Luminex,Corporation (Nasdaq: LMNX ), the ... for Planet xMAP Europe 2007, the company,s,annual European ... 2-3 October at the Berlage,s Exchange in Amsterdam, ...
Cached Biology Technology:Midwest Research Institute Launches Center for Biological Safety and Security (CBS2) 2Luminex Corporation Hosts the Fifth Annual Planet xMAP Europe 2007 Symposium 2Luminex Corporation Hosts the Fifth Annual Planet xMAP Europe 2007 Symposium 3
(Date:5/21/2013)... concept of "place" is increasingly being considered in ... have a new resource that can help them ... with the places in their lives. , ... new book co-edited by the Pacific Northwest Research ... human-centered approach to conservation. The book is published ...
(Date:5/21/2013)... University researchers have developed a new method for ... holes in the cell surface. The technique could ... related biological fields. , Bulk electroporation a ... reversible nanopores in the cell membrane that are ... is an increasingly popular method of cell transfection. ...
(Date:5/21/2013)... at Chicago College of Medicine will study gender differences in ... energy source -- and how changes in fat metabolism play ... 4-year grant from the National Heart, Lung and Blood Institute. ... for energy. These changes may play a major role in ... and women, says E. Douglas Lewandowski, director of the UIC ...
Breaking Biology News(10 mins):Single-cell transfection tool enables added control for biological studies 2Do men's and women's hearts burn fuel differently? 2
... worm, a tiny soil-dwelling nematode worm but the implications ... a recent study authored by University of Nevada, Reno researcher ... of the Caenorhabditis elegans worm was published in ... "Circadian rhythms are important in all organisms because they regulate ...
... Research Council (BBSRC) at the University of Oxford have uncovered ... evidence of complex multicellular animal life appears around 550 million ... sharply from 3% to their modern day level of 21%. ... that humans share a method of sensing oxygen with the ...
... Sinai School of Medicine today announced that the National ... the National Institutes of Health (NIH), has renewed funding ... Experimentation (PRIME). This program seeks to develop easy-to-use, predictive ... individuals affected by the H1N1 and 1918 influenza viruses ...
Cached Biology News:Breakthrough in worm research has implications for human disease studies 2550 million years ago rise in oxygen drove evolution of animal life 2Consortium studying mathematical modeling of influenza infection 2